Intranasal Bevacizumab for HHT-Related Epistaxis

Completed · Phase 4 · Has a placebo group

Conditions studied: HHT, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nose Bleeds, Nasal Bleeding

In brief

This is a randomized, controlled, double-blind, placebo-controlled trial of intranasal Avastin (bevacizumab) injection versus saline control for control of HHT-related epistaxis when used in conjunction with bipolar electrocautery.

Key facts

Study ID

NCT02389959

Run by

Stanford University

People needed

40

Starts

2014-08-04

Expected to finish

2020-01-23

Last updated by the study team

2021-09-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient carries a diagnosis of hereditary hemorrhagic telangiectasia (HHT)
• The patient is to undergo treatment with electrocautery in the operating room under endoscopic visualization
• The patient is able to give informed consent
• The patient is at least 18 years old

You may not qualify if…

• The patient has had prior treatment with systemic or nasal bevacizumab within the past year
• The patient has undergone electrocautery for epistaxis within the 6 months prior to study enrollment
• The patient is a minor
• The patient is pregnant
• The patient is incapable of understanding the consent process
• The patient has a history of HIV or another known cause of immunosuppression, or is actively taking immunosuppressive medications due to organ transplantation, rheumatoid disease, or other medical conditions.

Where it is running

• Stanford University Department of Otolaryngology- Head and Neck Surgery — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.